Galectin Announces Early Warrant Exercise by 10X Fund, Issues Update on Cash Position
October 17, 2013 at 08:09 AM EDT
Galectin Therapeutics (Nasdaq: GALT ), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that 10X Fund has exercised 300,000 common stock purchase warrants of Galectin Therapeutics at $3 per share for total cash proceeds of $900,000. The warrants were scheduled to expire on February 12, 2014.
